Charles River Laboratories (CRL)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	474,624	474,950	484,034	496,335	486,226	436,394	443,347	422,474	390,982	396,595	396,078	375,065	364,304	301,461	271,362	247,655	252,019	231,336	218,894	228,875
Total stockholders’ equity	US$ in thousands	3,596,880	3,305,990	3,251,700	3,108,600	2,976,290	2,626,850	2,647,710	2,610,180	2,534,820	2,426,570	2,318,440	2,183,930	2,114,600	1,896,940	1,752,640	1,651,980	1,634,580	1,532,310	1,455,070	1,398,110
ROE		13.20%	14.37%	14.89%	15.97%	16.34%	16.61%	16.74%	16.19%	15.42%	16.34%	17.08%	17.17%	17.23%	15.89%	15.48%	14.99%	15.42%	15.10%	15.04%	16.37%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $474,624K ÷ $3,596,880K
= 13.20%

The return on equity (ROE) of Charles River Laboratories has shown some fluctuations over the past few quarters. The ROE has ranged from a low of 13.20% to a high of 17.23% during the period under review. Despite the fluctuations, the ROE has generally been above 15% in most quarters, indicating that the company has been effectively utilizing its shareholders' equity to generate profits. The upward trend in ROE from 2020 to early 2022 shows an improvement in the company's profitability and efficiency in generating returns for its shareholders. However, there has been a slight decline in ROE in recent quarters, possibly indicating challenges or changes in the company's operations or market conditions. Overall, a sustained ROE above 15% demonstrates that Charles River Laboratories has been able to create value for its shareholders through efficient use of their equity.